HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The Transfusion Alternatives Preoperatively in Sickle Cell Disease (TAPS) study: a randomised, controlled, multicentre clinical trial.

AbstractBACKGROUND:
No consensus exists on whether preoperative blood transfusions are beneficial in patients with sickle-cell disease. We assessed whether perioperative complication rates would be altered by preoperative transfusion.
METHODS:
We did a multicentre, randomised trial. Eligible patients were aged at least 1 year, had haemoglobin SS or Sβ(0)thalassaemia sickle-cell-disease subtypes, and were scheduled for low-risk or medium-risk operations. Patients were randomly assigned no transfusion or transfusion no more than 10 days before surgery. The primary outcome was the proportion of clinically important complications between randomisation and 30 days after surgery. Analysis was by intention to treat.
FINDINGS:
67 (96%) of 70 enrolled patients-33 no preoperative transfusion and 34 preoperative transfusion-were assessed. 65 (97%) of 67 patients had the haemoglobin SS subtype and 54 (81%) were scheduled to undergo medium-risk surgery. 13 (39%) of 33 patients in the no-preoperative-transfusion group had clinically important complications, compared with five (15%) in the preoperative-transfusion group (p=0.023). Of these, 10 (30%) and one (3%), respectively, had serious adverse events. The unadjusted odds ratio of clinically important complications was 3.8 (95% CI 1.2-12.2, p=0.027). 10 (91%) of 11 serious adverse events were acute chest syndrome (nine in the no-preoperative-transfusion group and one in the preoperative-transfusion group). Duration of hospital stay and readmission rates did not differ between study groups.
INTERPRETATION:
Preoperative transfusion was associated with decreased perioperative complications in patients with sickle-cell disease in this trial. This approach could, therefore, be beneficial for patients with the haemoglobin SS subtype who are scheduled to undergo low-risk and medium-risk surgeries.
FUNDING:
NHS Blood and Transplant.
AuthorsJo Howard, Moira Malfroy, Charlotte Llewelyn, Louise Choo, Renate Hodge, Tony Johnson, Shilpi Purohit, David C Rees, Louise Tillyer, Isabeau Walker, Karin Fijnvandraat, Melanie Kirby-Allen, Eldon Spackman, Sally C Davies, Lorna M Williamson
JournalLancet (London, England) (Lancet) Vol. 381 Issue 9870 Pg. 930-8 (Mar 16 2013) ISSN: 1474-547X [Electronic] England
PMID23352054 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2013 Elsevier Ltd. All rights reserved.
Chemical References
  • Hemoglobin, Sickle
Topics
  • Acute Chest Syndrome (etiology, prevention & control)
  • Adolescent
  • Adult
  • Anemia, Sickle Cell (blood, complications, therapy)
  • Blood Transfusion
  • Canada
  • Child
  • Child, Preschool
  • Europe
  • Female
  • Hemoglobin, Sickle (metabolism)
  • Humans
  • Infant
  • Male
  • Odds Ratio
  • Perioperative Period
  • Postoperative Complications (prevention & control)
  • Surgical Procedures, Operative (adverse effects)
  • Treatment Outcome
  • beta-Thalassemia (therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: